Prescient Tightens Governance With Updated Securities Trading Policy

An update from Prescient Therapeutics Limited ( (AU:PTX) ) is now available.

Prescient Therapeutics Limited has updated and reapproved its Securities Trading Policy, which governs how directors, officers, employees, consultants, contractors and their closely related parties may deal in the company’s securities. The policy, most recently reviewed and approved on 24 February 2026, reiterates compliance obligations under Australian insider trading laws and requires internal clearance procedures before trading, reinforcing governance standards and reducing legal and reputational risk for the company and its stakeholders.

The policy defines which financial instruments are covered, including shares, options, rights, warrants and derivatives, and clarifies that insider trading prohibitions extend to dealing, procuring others to deal, and tipping confidential information. By formalising these rules and encouraging personnel to seek guidance from the CEO or Company Secretary when in doubt, Prescient aims to strengthen internal controls, promote market integrity and signal robust corporate governance to investors and regulators.

The most recent analyst rating on (AU:PTX) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Prescient Therapeutics Limited stock, see the AU:PTX Stock Forecast page.

More about Prescient Therapeutics Limited

Prescient Therapeutics Limited is an Australian biotechnology company focused on developing cancer therapies. The company operates in the life sciences sector, targeting oncology indications through advanced therapeutic platforms and related drug development programs.

Average Trading Volume: 2,213,435

Technical Sentiment Signal: Hold

Current Market Cap: A$67.3M

For detailed information about PTX stock, go to TipRanks’ Stock Analysis page.